Cancer’s not fair. But accessing treatment should be.
Currently patients in Ontario and Atlantic Canada face two-tiered and out-of-date cancer systems that are riddled with administrative hurdles, out-of-pocket costs to the patient and significant delays for at-home cancer treatments.
Canada’s Western provinces treat take-home cancer drugs and hospital-administered cancer drugs equally, irrespective of the patient’s cancer type, age, or income. Patients receive their treatment when they need it and without personal cost.
The CanCertainty Coalition is the united voice of 40 Canadian patient groups, cancer health charities and caregiver organizations working with oncologists and cancer care professionals to improve the affordability and accessibility of cancer treatment.
Ontario and the Atlantic provinces are letting patients down. It’s time to level up and put patients first.
Click on a province below to find out how to help.
CanCertainty’s Hot Topics Webinar Series
Join CanCertainty’s Hot Topics Webinar Series for a discussion on "MFN and the Future of Cancer Drug Access in Canada" on Thursday, August 20 at 1:00 pm EDT.
In 2025, the United States introduced a Most-Favoured-Nation (MFN) drug pricing policy that links U.S. drug prices to those in other countries, including Canada. What could this mean for access to cancer medicines in Canada?
The webinar will kick off with an overview of MFN by 3Sixty Public Affairs Bill Dempster, who will then moderate a discussion with international trade expert Laura Dawson (founder of the Future Borders Coalition), global pharma pricing expert Laurene Redding (with Gilead Canada) and oncologist and pharmaceutical policy expert Dr. David Stewart (co-founder of the Life Saving Therapies Network. CanCertainty’s Bob Bick will help reflect on the broader cancer community’s questions and concerns.
Key discussion topics:
- How the MFN policy works
- Why it was introduced
- Potential impacts on access to cancer treatments in Canada
- Possible solutions to help protect timely patient access